Gene Expression Profiling for ASD Ileocolitis Biomarker Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective molecular characterization and diagnosis for gastrointestinal disorders in children with autism spectrum disorders (ASD), making it difficult to distinguish between ASD-associated inflammatory disorders and conventional inflammatory bowel diseases.
Innovation Solution
The use of specific biomarkers such as IL2RA, IGF2BP1, TNFRSF12A, rs1127155, and rs6460055 polymorphisms, along with gene expression profiling, to diagnose gastrointestinal disorders and autism spectrum disorder in children, enabling accurate identification and differentiation from other inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for gastrointestinal disorders in children with ASD, then the diagnostic process is simple and accessible, but the ability to accurately distinguish between ASD-associated inflammatory disorders and conventional inflammatory bowel diseases is insufficient
Solution Approach 1:
The patent applies parameter changes by measuring the expression levels of specific genes (IL2RA, IGF2BP1, TNFRSF12A) and polymorphisms (rs1127155, rs6460055) to differentiate between ASD-associated gastrointestinal disorders and conventional inflammatory bowel diseases. This molecular parameter approach enables accurate diagnosis by detecting specific biological markers that distinguish the two conditions, transforming the diagnostic process from clinical observation to precise molecular measurement.
2Measurement precision
If molecular characterization methods are implemented to diagnose gastrointestinal disorders in ASD children, then diagnostic precision is improved, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent extracts specific molecular markers (gene expression profiles of IL2RA, IGF2BP1, TNFRSF12A and polymorphisms rs1127155, rs6460055) from the complex biological system of ASD children's gastrointestinal tissue. By isolating and measuring these specific markers, the method achieves precise molecular characterization without needing to analyze the entire genomic landscape, thus improving diagnostic accuracy while managing complexity through targeted selection of key markers.
3Adaptability or versatility
If gene expression profiling is used to identify unique profiles in ASD children with ileocolitis, then disease differentiation capability is enhanced, but the cost and complexity of the diagnostic approach increase
Solution Approach 1:
The patent segments the complex task of gastrointestinal disorder diagnosis in ASD children by focusing on specific gene expression profiles (IL2RA, IGF2BP1, TNFRSF12A) and polymorphisms (rs1127155, rs6460055) that are characteristic of ileocolitis. This segmentation allows the diagnostic system to differentiate between various gastrointestinal conditions by measuring specific molecular segments rather than attempting to analyze all possible genetic and clinical parameters simultaneously, thereby enhancing differentiation capability while controlling system complexity.
Data Source
AI summary
The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.